Acknowledgments, Contributors, and Participants

Acknowledgments

Contraception and Fertility Care Unit, Department of Sexual and Reproductive Health and Research, World Health Organization; CommunicateHealth.

Contributors

Courtney Baker, University of Texas Southwestern Medical Center, Dallas, Texas; Divya Dethier, University of Hawaii, Honolulu, Hawaii; Sophia Garbarino, Emory University, Atlanta, Georgia; Heather Gold, Emory University, Atlanta, Georgia; Emma Halper, Emory University, Atlanta, Georgia; Nathalie Kapp, International Planned Parenthood Federation, London, England; Gopika Krishna, Columbia University, New York, New York; Marielle Meurice, University of California-San Diego, San Diego, California; Stephanie Ramer, CDC, Atlanta, Georgia; Jessica Rodenhizer, CDC, Atlanta, Georgia; Nisha Verma, Emory University, Atlanta, Georgia; Steffanie Wright, Harvard University, Boston, Massachusetts

U.S. Medical Eligibility Criteria for Contraceptive Use and U.S. Selected Practice Recommendations for Contraceptive Use Meeting Participants

CDC Guideline Development Group for U.S. Medical Eligibility Criteria for Contraceptive Use and U.S. Selected Practice Recommendations for Contraceptive Use

Anna Brittain, Megan Cohen, Kathryn Curtis, Kendra Hatfield-Timajchy, Katherine Kortsmit, Antoinette Nguyen, Emily Snyder, Naomi Tepper, Maura Whiteman, Lauren Zapata, CDC, Atlanta, Georgia.

Invited Meeting Participants, January 21, 2022, Virtual

Diana Blithe, National Institute of Child Health and Human Development, Bethesda, Maryland; Mary Cushman, University of Vermont, Burlington, Vermont; Alison Edelman, Oregon Health & Science University, Portland, Oregon; Mary Lyn Gaffield, Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland; Andra James, Duke University Medical Center, Durham, North Carolina; Andrew Kaunitz, University of Florida, Jacksonville, Florida; Kathryn Lindley, Washington University Center for Women's Heart Disease, St. Louis, Missouri; Chelsea Morroni, United Kingdom Faculty of Sexual and Reproductive Healthcare, Edinburgh, Scotland; Lydia Pecker, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sarah Prager, University of Washington, Seattle, Washington; Michael Streiff, Johns Hopkins University School of Medicine, Baltimore, Maryland; Bethany Samuelson Bannow, Oregon Health & Science University, Portland, Oregon; Angeline Ti, Wellstar Atlanta, Atlanta, Georgia; Carolyn Westhoff, Columbia University, New York, New York.

Conflicts of interest for invited meeting participants, January 21, 2022, virtual

Michael Streiff, consultation for Bayer, Janssen, Pfizer, and Portola, recipient of grants to support research from Boehringer Ingelheim, Janssen, Novo Nordisk, Portola, Sanofi, Tremeau pharmaceuticals, conducted lectures for Bayer, Pfizer, and Portola; Alison Edelman, consultant for American College of Obstetricians and Gynecologists (ACOG), supports medical eligibility criteria activities for World Health Organization, Oregon Health & Science University receives research funding from Merck and HRA Pharma; Andrew Kaunitz, University of Florida College of Medicine receives financial support for clinical trials sponsored by Merck and Mithra; Carolyn Westhoff, editor of Contraception, consultant for Merck and Bayer, member of a number of data safety and monitoring boards for overseeing phase 4 Food and Drug Administration–mandated studies of new contraceptives, Columbia University receives research funding for clinical trials for each new contraceptive discussed.

CDC Subject Matter Experts and Attendees, January 21, 2022, Virtual

Wanda Barfield, Brook Belay, Elizabeth Clark, Shanna Cox, Suzanne Folger, Sarah Foster, Craig Hooper, Jessica Rodenhizer, Tanvi Suresh, Angela Thompson-Paul, Lee Warner, CDC, Atlanta, Georgia.

Invited Meeting Participants, January 25–26, 2022, Virtual

Elise Berlan, American Academy of Pediatrics and Nationwide Children's Hospital, Columbus, Ohio; Sonya Borrero, University of Pittsburgh, Pittsburgh, Pennsylvania; Anitra Beasley Brod, Society of Family Planning and Baylor College of Medicine, Houston, Texas; Nicole Chaisson, American Academy of Family Physicians and University of Minnesota, Minneapolis, Minnesota; Alison Edelman, Oregon Health & Science University, Portland, Oregon; Mary Lyn Gaffield, Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland; Emily Godfrey, University of Washington, Seattle, Washington; June Gupta, Planned Parenthood Federation of America, New York, New York; Samantha Hyacinth, Reproductive Health Access Project, New York, New York; Jessica Marcella, Office of Population Affairs, U.S. Department of Health and Human Services, Washington, DC; Chelsea Morroni, United Kingdom Faculty of Sexual and Reproductive Healthcare, Edinburgh, Scotland; Latoya Patterson, National Medical Association and Duke University, Durham, North Carolina; Sarah Prager, University of Washington, Seattle, Washington; Sarah Romer, Office of Population Affairs, U.S. Department of Health and Human Services, Washington, DC; Lisa Stern, Coalition to Expand Contraceptive Access, Sacramento, California; Maria Trent, Society for Adolescent Health and Medicine and Johns Hopkins University School of Medicine, Baltimore, Maryland; Nisha Verma, American College of Obstetricians and Gynecologists, Washington, DC; Carolyn Westhoff, Columbia University, New York, New York.

Conflicts of interest for invited meeting participants, January 25–26, 2022, virtual

Elise Berlan, Nexplanon clinical trainer for Merck/Organon, received research funding from Merck/Organon; Nicole Chaisson, Nexplanon trainer for Organon; Alison Edelman, consultant for American College of Obstetricians and Gynecologists (ACOG), supports medical eligibility criteria activities for World Health Organization, Oregon Health & Science University receives research funding from Merck and HRA Pharma; Carolyn Westhoff, editor of Contraception, consultant for Merck and Bayer, member of a number of data safety and monitoring boards for overseeing phase 4 Food and Drug Administration–mandated studies of new contraceptives, Columbia University receives research funding for clinical trials for each new contraceptive discussed.

CDC Subject Matter Experts and Attendees, January 25–26, 2022, Virtual

Wanda Barfield, Elizabeth Clark, Shanna Cox, Suzanne Folger, Sarah Foster, Jennifer Nelson, Jessica Rodenhizer, Tanvi Suresh, Lee Warner, CDC, Atlanta, Georgia.

Systematic Review Presenters, January 25–27, 2023, Atlanta, Georgia

Courtney Baker, Megan Cohen, Kathryn Curtis, Emma Halper, Katherine Kortsmit, Antoinette Nguyen, Emily Snyder, Naomi Tepper, Lauren Zapata, CDC, Atlanta, Georgia.

Invited Meeting Participants, January 25–27, 2023, Atlanta, Georgia

Amy Lansky, CDC, Atlanta, Georgia (Chair); Elise Berlan, American Academy of Pediatrics and Nationwide Children's Hospital, Columbus, Ohio; Diana Blithe, National Institute of Child Health and Human Development, Bethesda, Maryland; Sonya Borrero, Office of Population Affairs, U.S. Department of Health and Human Services and University of Pittsburgh, Pittsburgh, Pennsylvania; Kristyn Brandi, American College of Obstetricians and Gynecologists, Washington, DC; Anitra Beasley Brod, Society of Family Planning and Baylor College of Medicine, Houston, Texas; Anna Burgner, Vanderbilt University, Nashville, Tennessee; Nicole Chaisson, American Academy of Family Physicians and University of Minnesota, Minneapolis, Minnesota; Mitchell Creinin, University of California-Davis, Davis, California; Mary Cushman, University of Vermont, Burlington, Vermont; Ann Dude, Society for Maternal-Fetal Medicine and University of North Carolina, Chapel Hill, North Carolina; Alison Edelman, Oregon Health & Science University, Portland, Oregon; Mary Lyn Gaffield, World Health Organization, Geneva, Switzerland; Emily Godfrey, University of Washington, Seattle, Washington; Ashira Greenberg, Patient Advocate and Sexual Health Educator, New York, New York; Edith Guilbert, Institut National de Santé Publique du Québec, Quebec City, Quebec; June Gupta, Planned Parenthood Federation of America, New York, New York; Sadia Haider, Rush University, Chicago, Illinois; Andra James, Duke University, Durham, North Carolina; Paritosh Kaul, Society for Adolescent Health and Medicine and Medical College of Wisconsin, Milwaukee, Wisconsin; Andrew Kaunitz, University of Florida, Jacksonville, Florida; Nancy Kidula, World Health Organization, Geneva, Switzerland; Sari Kives, North American Society for Pediatric and Adolescent Gynecology and University of Toronto Hospital for Sick Children, Toronto, Ontario; David Klein, Uniformed Services University, Travis Air Force Base, Fairfield, California; Anandi Kotak, Food and Drug Administration, Washington, DC; Aaron Lazorwitz, University of Colorado, Boulder, Colorado; Yvonne Malloy, National Hispanic Medical Association, Washington, DC; Monica McLemore, University of Washington, Seattle, Washington; Isabel Morgan, National Birth Equity Collaborative, New Orleans, Louisiana; Chelsea Morroni, United Kingdom Faculty of Sexual and Reproductive Healthcare, Edinburgh, Scotland; Brian Nguyen, University of Southern California, Los Angeles, California; Juno Obedin-Maliver, World Professional Association for Transgender Health and Stanford University, Palo Alto, California; Tina Pattara-Lau, Indian Health Service, Phoenix, Arizona; Lydia Pecker, Johns Hopkins University School of Medicine, Baltimore, Maryland; Michael Policar, University of California-San Francisco, San Francisco, California; Elisabeth Quint, University of Michigan, Ann Arbor, Michigan; Mia Robinson, Patient Advocate and Sickle Cell Awareness 365, Atlanta, Georgia; Sarah Romer, Office of Population Affairs, U.S. Department of Health and Human Services, Washington, DC; Monika Sarkar, University of California-San Francisco, San Francisco, California; Maria Small, National Medical Association and Duke University, Durham, North Carolina; Lisa Stern, Coalition to Expand Contraceptive Access, Sacramento, California; Michael Streiff, Johns Hopkins University School of Medicine, Baltimore, Maryland; Ivana Thompson, Physicians for Reproductive Health and University of Washington, Seattle, Washington; Angeline Ti, Reproductive Health Access Project and Wellstar Health System, Inc., Atlanta, Georgia; Carolyn Westhoff, Columbia University, New York, New York; Katharine White, Boston University School of Medicine, Boston, Massachusetts; Tracey Wilkinson, Indiana University, Bloomington, Indiana.

Conflicts of interest for invited meeting participants, January 25–27, 2023, Atlanta, Georgia

Elise Berlan, Nexplanon clinical trainer for Merck/Organon; Nicole Chaisson, Nexplanon clinical trainer for Merck/Organon; Mitchell Creinin, received honorarium from Gedeon Richter, Mayne, and Organon, served on advisory board for Gedeon Richter, GlaxoSmithKline, OLIC, and Organon, consulted for Danco, Estetra SRL, FHI360, Mayne, and Medicines360, University of California-Davis, receives contraceptive research funding from Chemo Research SL, Evofem, Medicines360, Merck, Sebela, and National Institutes of Health National Institute of Child Health and Human Development; Alison Edelman, receives travel reimbursement from American College of Obstetricians and Gynecologists, World Health Organization, CDC, and Gynuity for committee activities, receives royalties from Up to Date, Inc., Oregon Health & Science University receives research funding from Oregon Health & Science University Foundation, Merck, HRA Pharma, Bill & Melinda Gates Foundation, and National Institutes of Health; Emily Godfrey, works with Organon and received honoraria as Nexplanon trainer; Andrew Kaunitz, consultant to Mithra, University of Florida receives research support from Bayer, Merck, Mithra, and Mylan; Aaron Lazorwitz, receives research support from Organon for investigator-initiated research with the etonogestrel contraceptive implant; Yvanna Marlin-Guanga, employed under CommunicateHealth, contractor for U.S. Medical Eligibility Criteria for Contraceptive Use and U.S. Selected Practice Recommendations for Contraceptive Use January 2023 meeting; Rachel Martin, employed under CommunicateHealth, contractor for U.S. Medical Eligibility Criteria for Contraceptive Use and U.S. Selected Practice Recommendations for Contraceptive Use January 2023 meeting; Lydia Pecker, consulted for Novo Nordisk and Global Blood Therapeutics, receives research support from Alexion, National Institutes of Health National Heart, Lung, and Blood Institute, Mellon Foundation, American Society of Hematology, and Doris Duke Foundation; Michael Streiff, consultant for CSL Behring data safety monitoring board member, Janssen consultant on management of cancer-associated thromboembolism, and Pfizer consultant on anticoagulation for venous thromboembolism; Katharine White, receives research support through institution from Bayer, Merck, and Evofem; Tracey Wilkinson, receives project funding from Bayer, Cooper Surgical, and Organon, and nonpaid consultant for HRA Pharma.

CDC Subject Matter Experts and Attendees, January 25–27, 2023, Atlanta, Georgia

Karon Abe, Wanda Barfield, Brook Belay, Emily Cartwright, Elizabeth Clark, Shanna Cox, Suzanne Folger, Sarah Foster, Sophia Garbarino, Karen Hacker, Lisa Hollier, Craig Hooper, Bajha Jordan, Michele Mandel, Meda Pavkov, Stephanie Ramer, Brenda Reed, Jessica Rodenhizer, Lisa Romero, Laura Schieve, Andrea Stewart, Heather Tevendale, Angela Thompson-Paul, Lee Warner, Steffanie Wright, CDC, Atlanta, Georgia.

External Reviewers

Genevieve M. Hofmann, University of Colorado, Aurora, Colorado; Raegan McDonald-Mosley, Power to Decide, Washington, DC; Bethany Samuelson Bannow, Oregon Health & Science University, Portland, Oregon; Nichole Tyson, Stanford University, Palo Alto, California.

Conflicts of Interest

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed. To promote transparency, all meeting participants were asked to disclose potential conflicts of interest to CDC before the expert meeting and to report potential conflicts of interest during the introductory portion of the expert meeting. All potential conflicts of interest disclosed by meeting participants are listed. No participants were excluded from discussion based on potential conflicts of interest. CDC staff members who ultimately decided and developed these recommendations have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters relevant to these recommendations.